dostarlimab

Drug name: dostarlimab

English name: dostarlimab

Indications

Dostarlimab is a programmed death receptor 1 (PD-1) blocking antibody, suitable for the treatment of adult patients with recurrent or advanced mismatch repair deficiency (dMMR): endometrial cancer, solid tumors.

Dosage

Dosage 1 to 4: 500 mg every 3 weeks.

Start subsequent doses 3 weeks after the 4th dose (5th dose): 1000 mg every 6 weeks.

Intravenous infusion for more than 30 minutes.

Adverse Reactions

The most common adverse reactions (≥20%) in patients with dMMR solid tumors are fatigue/asthenia, anemia, diarrhea, and nausea. The most common grade 3 or 4 laboratory abnormalities (≥2%) were lymphopenia, decreased sodium, increased alkaline phosphatase, and decreased albumin.

Precautions

Immune-mediated adverse reactions may be serious or fatal and may occur in any organ system or tissue, including: immune-mediated pneumonitis, immune-mediated colitis, immune-mediated hepatitis, immune-mediated endocrinopathy, immune-mediated nephritis renal insufficiency, immune-mediated dermatological adverse reactions, and solid organ transplant rejection. Monitor for signs and symptoms of immune-mediated adverse reactions. Clinical chemistry markers, including liver enzymes, creatinine, and thyroid function, were assessed at baseline and periodically during treatment. Not given or permanently terminated JEMPERLI and administer corticosteroids based on the severity of the reaction.

Infusion-related reactions: Interrupt, slow down the infusion rate, or permanently discontinue dotalizumab depending on the severity of the reaction.

Complications of allogeneic hematopoietic stem cell transplantation (HSCT): after receiving PD-1/PD-L1 Fatal and other serious complications may occur in patients who receive allogeneic HSCT before or after blocking antibody therapy.

Embryo-fetal toxicity: Can cause fetal harm. Advise women of childbearing potential of the potential risk to the fetus and to use effective contraception.

About dotilizumab

Dotilizumab is a prescription medicine used to treat adults with certain cancers that have been shown to be mismatch repair deficient (dMMR) by laboratory tests and in which the cancer has come back, or has spread or cannot be removed with surgery (advanced cancer). Dotalizumab may be used if:

You have a type of uterine cancer called endometrial cancer and have received platinum-containing chemotherapy, but it did not work or no longer works.

Solid tumors that progress during or after treatment and for which there are no satisfactory treatment options.

It is not known whether dotalizumab is safe and effective in children.